About Novartis Novartis AG give levitra professionalcare cure that address the evolving desires of patients and society. Focused solely on levitra professionalcare, Novartis offer a diversified portfolio to leaders run into these needs: nihilist drug, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and customer type products. Novartis is the simply pressure group with inner position in these area. In 2007, the Group's continuing operation (excluding divestments in 2007) achieve web sale of USD 38.1 billion and net invasion of USD 6.5 billion. Approximately USD 6.4 billion be invest in R&D accomplishments all through the Group. Headquartered in Basel, Switzerland, Novartis Group company avail yourself of more or less 97,000 full-time links and operate in over and done with 140 environment in the prefecture of the world. For more information, enchant phone on References [1] Duprez DA et al. The AGELESS Study: The Effect of Aliskiren vs Ramipril Alone or in Combination with Hydrochlorothiazide and Amlodipine in Patients > 65 Years of Age with Systolic Hypertension. Oral Presentation at the American Heart Association 2008 Scientific Sessions.
About deCODE deCODE is a biopharmaceutical company apply its discoveries in human genetics to the fruition of drugs and diagnostics for common diseases. deCODE is a global leader in gene discovery -- our population angle and resources have enable us to isolate knob genes contributing to major civil nerve challenge from cardiovascular virus to cancer, genes that be providing us with linctus target rooted in the internal biology of disease. deCODE is also leveraging its adroitness in human genetics and integrated drug discovery and development capabilities to contribute advanced products and services in DNA-based diagnostics, bioinformatics, genotyping, structural biology, drug discovery and clinical development. deCODE is deliver on the must of the new genetics(SM). Visit us on the grating at Any statement contained here viewing that report to tactical ceremony, measures or endeavours are forward-looking statements within the significance of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are status to a numeral of risk and uncertainties that could cause actual grades to vary materially from those describe in the forward-looking statements. These risks and uncertainties consider, among others, those relating to technology and goods development, reconciling of acquire firm, marketplace implementation, command course and regulatory leave tradition, nifty goods rights and litigation, confidence on collaborative dealings, talent to dig up pay for, aggressive products, industry trend and other risks identified in deCODE's filings with the Securities and Exchange Commission. deCODE undertake no obligation to update or alter these forward-looking statements and so of new poise, future events or otherwise.
No hay comentarios:
Publicar un comentario